Association of SGLT2 Inhibitor With Stroke in Type 2 Diabetes With Diabetic Retinopathy: A Multicenter Electronic Health Record Data Study
Authors' conclusion
SGLT2i was associated with lower stroke risk, particularly HS, in patients with T2D and DR.
Study context
- Population
- Adults with T2D and Diabetic Retinopathy (DR), TriNetX Research Network13,778 per group after matching
- Participants
- 13,778 vs 13,778
- Exposure
- SGLT2i vs DPP-4i/metformin
- SGLT2in = 13,778
- Dipeptidyl peptidase-4 inhibitors/metforminn = 13,778reference
- Outcome
- Ischemic stroke (IS) and hemorrhagic stroke (HS) risks
- Follow-up
- 1, 3 and 5 years
Methodological detailsmulticenter, 1:1 propensity score matching
- Multicenter
- 1:1 propensity score matching
Main finding
As reported in the abstract
SGLT2i vs dipeptidyl peptidase-4 inhibitors/metforminHazard ratio (95% CI)
HS at 1 year
0.76(0.56–0.93)
HS at 3 years
0.79(0.59–0.90)
HS at 5 years; NNT 100
0.73(0.60–0.89)
- Ischemic stroke (IS) risk reduction emerged at 5 years: HR
- 0.92 (0.85-0.99); NNT 34 (95% CI)
Observational data: associations, not effects.
Further findings
Hemorrhagic stroke (HS) risk in early-stage DR and HbA1c > 7% · 1, 3 and 5 years
- HS at 1 year: HR
- 0.57 (0.37-0.89) (95% CI)
- HS at 3 years: HR
- 0.61 (0.41-0.83) (95% CI)
- HS at 5 years: HR
- 0.64 (0.44-0.84) (95% CI)
Sensitivity analyses: 5-year HS risk in neuropathy, nephropathy and CKD
- Consistent 5-year reductions in HS risk; NNT neuropathy
- 91
- NNT nephropathy
- 59
- NNT CKD
- 84
Original publication
Association of SGLT2 Inhibitor With Stroke in Type 2 Diabetes With Diabetic Retinopathy: A Multicenter Electronic Health Record Data Study. Diabetes Obes Metab. Published 13 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →